Literature DB >> 30005899

The Effect of a Parental Visitation Program on Emergence Delirium Among Postoperative Children in the PACU.

WooYoung In, Young Man Kim, Hee Soon Kim, SeoHee Hong, YuRi Suh, Yerin Cha, Naeun Kim, JongWon Kim, HyunJi Kang, HyoEun Kwon, YangSoo Kim, Wyunkon Park.   

Abstract

PURPOSE: The purpose of this study was to examine the effects of parental presence on the incidence of emergence delirium (ED) of children in the postanesthesia care unit (PACU).
DESIGN: A quasi-experimental pretest and post-test study with nonequivalent and nonsynchronized control groups.
METHODS: About 93 children aged 3 to 6 years undergoing general anesthesia for tonsillectomy were divided into two groups: parental presence and absence. ED was recorded using the Pediatric Anesthesia Emergence Delirium Scale at 0, 10, 20, and 30 minutes after PACU admission.
FINDINGS: ED score at each time point in the experimental group was lower than the control group, but not statistically significant. ED score in the experimental group significantly decreased over time (F = 6.98; P = .010).
CONCLUSIONS: Parental visitation programs could be effective on the degree of ED in children in the PACU setting. This result may contribute to the establishment of PACU visitation program policy in South Korea.
Copyright © 2018 American Society of PeriAnesthesia Nurses. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PACU; emergence delirium; parental visitation program; perioperative nursing

Mesh:

Year:  2018        PMID: 30005899     DOI: 10.1016/j.jopan.2018.04.003

Source DB:  PubMed          Journal:  J Perianesth Nurs        ISSN: 1089-9472            Impact factor:   1.084


  1 in total

1.  Dexmedetomidine for the prevention of emergence delirium and postoperative behavioral changes in pediatric patients with sevoflurane anesthesia: a double-blind, randomized trial.

Authors:  Mengzhu Shi; Shuai Miao; Tianchu Gu; Dongyue Wang; Hui Zhang; Jindong Liu
Journal:  Drug Des Devel Ther       Date:  2019-03-15       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.